Somapacitan-beco

Description

Sogroya (generic: somapacitan-beco) is a prescription injection solution made by Novo Nordisk for subcutaneous use. It contains somapacitan at 3.3 mg/mL strength and was approved under BLA761156, with marketing starting in May 2023. This information was generated using AI and is provided for informational and research purposes only.

Resources

Name Format Description Link
21 Access the FDA dataset for Somapacitan-beco — ANDA 761156 submitted by Mylan Institutional LLC https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761156

Tags

  • health-care
  • public-health
  • prescription-drugs
  • drug
  • pharmaceuticals

Topics

Categories